Nonclinical development strategies to optimise your clinical development programme
Being first to market with an innovator drug remains the ultimate goal for all, and most organisations are constantly reviewing ...Read more >
News
First Dose Administered in Phase I Trial of Novel Treatment for Cognitive Impairment Associated with Schizophrenia
February 27, 2023 Simbec-Orion are pleased to share that dosing with MDI-26478, Cardiff University’s Medicines Discovery Institute’s (MDI) potential novel ...Read more >
Mission Therapeutics Successfully Completes First Clinical Assessment for Lead DUB Program, MTX652
The successful delivery of another Phase I clinical trial by the team at Simbec-Orion has resulted in the achievement of ...Read more >
Patient recruitment strategies for rare disease trials
One of the key challenges facing researchers working on treatments for rare diseases is recruitment for clinical trials. Because these ...Read more >
The 4 Types of clinical trial monitoring
In recent decades, clinical trials and their methodologies have evolved significantly. New technologies have led to improved research methods, techniques ...Read more >
Advantages and Disadvantages of Clinical Outsourcing
Pharmaceutical companies all over the world outsource some or all elements of their clinical trials in order to better manage ...Read more >
Considerations in rare disease study design
Designing a clinical trial is a complex and challenging process. There are several key factors that researchers have to consider, ...Read more >
Sustained clinical response in a patient with metastatic breast cancer treated with MP0274
Today we celebrate the success of our colleague, and Scientific Advisory Board member, Dr Samson Fung. Dr Fung was recently ...Read more >
What is Research and Development in the Pharmaceutical Sector?
Pharmaceutical R&D is the process of developing drugs and pharmaceuticals so they are appropriate and safe for market use. The ...Read more >
Clinical Trial Data Management: Explained
Clinical data management (CDM) is one of the most integral processes in any clinical study. Data is at the heart ...Read more >
Simbec-Orion supports AL-S Pharma with Phase II ALS Study
Amyotrophic lateral sclerosis (ALS) is a rare, progressive neurodegenerative disease that affects the motor neurons controlling voluntary muscle movement. The ...Read more >
Welsh STEM Award Nominations for Two Simbec-Orion Scientists
We are thrilled that two of our Simbec-Orion colleagues are amongst the Welsh businesses and individuals shortlisted in the Wales ...Read more >